Migdal reports 5.37% Teva ownership stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Migdal Insurance & Financial Holdings Ltd. filed a Schedule 13G reporting beneficial ownership of 61,689,363 Teva Pharmaceutical Industries Ltd. ordinary shares, representing 5.37% of the class, based on 1,149,812,898 shares outstanding as of December 31, 2025.
The shares are held through various Migdal subsidiaries that manage insurance, pension, provident, mutual fund and portfolio accounts, each under independent management. As of January 20, 2026, the filing lists 107,000 shares held by Migdal Insurance Company Ltd., 53,935,231 shares by Migdal Sal Domestic Equities, and 7,647,132 shares by Migdal Mutual Funds Ltd.
The filing emphasizes that these securities are not held to change or influence control of Teva and that Migdal and its subsidiaries disclaim beneficial ownership beyond their actual economic interest.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Teva (TEVA) does Migdal Insurance & Financial Holdings report?
Does Migdal intend to influence control of Teva (TEVA) with this ownership?
What type of filing did Migdal submit regarding Teva (TEVA)?
On what date is Migdal’s ownership percentage in Teva (TEVA) calculated?
AI-generated analysis. How Rhea-AI works. Not financial advice.